Please assess the completion status of the following clinical trial:

Trial Title: LXRA Gene Polymorphisms and Response to Fenofibrate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Triglycerides equal to or above 150mg/dL or Low HDL (below 44 mg/dl for men or below 54 mg/dl for women)~* Must be able to swallow tablets~Exclusion Criteria:~* Known Coronary Heart Disease, symptomatic carotid artery disease, abdominal aortic aneurysm, diabetes, or Framingham risk score above 20%~* Pregnancy, malignancy, liver dysfunction, renal dysfunction, active alcohol abuse, history of unexplained muscle pain~* Current treatment with lipid lowering therapy, estrogens, androgens, progestins, thiazide diuretics, beta-blockers, glucocorticoids (other than inhaled), antihistamines, or chronic anti-inflammatory drugs~* Current treatment with the following the interacting drugs: ursodeoxycholic acid, ursodiol, cholestyramine, red yeast rice, glyburide, glipizide, warfarin, or cyclosporine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1-Fenofibrate then Placebo (Type: ACTIVE_COMPARATOR): 4 weeks of drug at 160 mg orally per day, 4 week washout, then 4 weeks of placebo
- 2 Placebo then Fenofibrate (Type: ACTIVE_COMPARATOR): 4 weeks of placebo then 4 week washout then 4 weeks of Fenofibrate at 160 mg/day orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).